Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Clinical Trial
Share your love
Promising Results for First Topical Treatment in DR
Exonate Ltd., a pioneering mRNA therapy company specializing in treatments for diabetic diseases, has announced that its lead ophthalmology asset, EXN407, successfully met prespecified endpoints in a phase Ib/IIa study for diabetic retinopathy and diabetic macular edema. During the trial,…
Vyjuvek Restores Vision in Teen with Rare Genetic Condition
Krystal Biotech’s topical gene therapy Vyjuvek (beremagene-geperpavec) has successfully restored the vision of a 13-year-old boy suffering from the rare genetic condition dystrophic epidermolysis bullosa (DEB), which scarred his eyes. The groundbreaking case, detailed in a recent publication in The…
Eyenovia’s Redwood City Facility Clears FDA Inspection
Eyenovia announced the successful completion of the FDA inspection for its facility in Redwood City, California, marking a significant milestone in the company’s manufacturing capabilities. This achievement signals the green light for the facility to engage in final assembly, packaging,…
Nicox and Kowa Strike Deal for NCX 470 in Japan
Nicox SA announced an agreement with Kowa, granting the latter exclusive rights in Japan for the development and commercialization of NCX 470, a promising nitric oxide (NO)-donating bimatoprost eye drop designed for reducing intraocular pressure (IOP) in individuals with glaucoma…
FDA Gives Green Light to OK-101 Trial for NCP Treatment
Okyo Pharma’s first investigational new drug (IND) application for OK-101 has been cleared by the U.S. Food and Drug Administration (FDA), marking a pivotal moment in the development of potential therapies for neuropathic corneal pain. Initially proposed as an open-label…
Low-Dose Atropine Eye Drops & Myopia Progression
According to the National Eye Institute (NEI), a trial conducted by the Pediatric Eye Disease Investigator Group (PEDIG) and funded by the NEI revealed that the use of low-dose atropine eye drops (concentration 0.01%) did not demonstrate superiority over a…
Glaukos Secures FDA Approval for iDose TR
Glaukos has received FDA approval for iDose TR (travoprost intracameral implant 75 mcg), a groundbreaking prostaglandin analog intracameral implant designed to reduce intraocular pressure (IOP) in individuals with ocular hypertension or open-angle glaucoma. The iDose TR procedure, sanctioned for a…
FDA Approves Vuity for Twice-Daily Dosing in Presbyopia
AbbVie, the parent company of Allergan, has announced that the FDA has granted approval for the use of Vuity (pilocarpine HCl ophthalmic solution) 1.25% twice a day in adults suffering from presbyopia. The second dose, consisting of an additional drop…
2023 Recap: Top 15 Firsts in Ophthalmology
In a year marked by groundbreaking achievements, the field of ophthalmology witnessed a series of historic firsts, pushing the boundaries of innovation and patient care. Here are the noteworthy milestones: Pioneering the integration of technology into glaucoma management, the world’s…
Aviceda’s IND Cleared by FDA for GA to AMD Treatment
Aviceda Therapeutics announced that the FDA has granted clearance for the IND for AVD-104. This clearance will allow the company to proceed with the initiation of Phase 2 clinical trials of its leading intravitreal ocular asset for the treatment of…